Trial Profile

A Phase I study with repeated doses of the Multiple Ascending Dose of RMC-035

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 31 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RMC 035 (Primary)
Indications Acute kidney injury; Radiation injuries
Focus Adverse reactions; First in man

Most Recent Events

31 Aug 2021 Status has been changed to completed as per guard therapeutics pipeline
14 Nov 2018 New trial record
09 Nov 2018 According to an A1M Pharma AB media release, the Swedish Medicines Agency has given permission to initiate the Phase I clinical trial of ROSgard. Single Ascending Dose part is expected to start in the first quarter of 2019 and Multiple Ascending Dose part in the second half of 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com